There’s a lot gone on since [the last guideline was published in] 2014, and it now doesn’t reflect best practice,’ said ...

In the largest study to date of 71 patients with refractory or relapsing ANCA-associated vasculitis, 65% achieved clinical remission with alemtuzumab treatment and a further 20% of patients had a ...

Prophylactic trimethoprim-sulfamethoxazole lowered serious infection risk in patients with ANCA-associated vasculitis, ...

Bosch and colleagues searched MEDLINE for studies published in English between 1966 and 2007 that evaluated the available treatments for antineutrophil cytoplasmic antibody (ANCA)-associated ...

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Avacopan has been found to be safer and to lead to fewer infections in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis ... unmet need for treatment strategies ...

In April 2025, Novartis Pharmaceuticals announced study is to establish the efficacy, safety, and tolerability of ...

VEXAS syndrome is known to be a mimicker of ANCA-associated vasculitis, making it a challenge to distinguish between the disorders. VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory ...

This research significantly enhances our understanding of the immune mechanisms driving ANCA-associated vasculitis and opens ... lead to more personalized treatment strategies and better outcomes ...

This research significantly enhances our understanding of the immune mechanisms driving ANCA-associated vasculitis and opens ... lead to more personalized treatment strategies and better outcomes ...